"Induction Chemotherapy" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Initial drug treatment designed to bring about REMISSION INDUCTION. It is typically a short-term and high-dose drug treatment that is followed by CONSOLIDATION CHEMOTHERAPY and then MAINTENANCE CHEMOTHERAPY.
| Descriptor ID |
D060828
|
| MeSH Number(s) |
E02.319.499 E02.860.500
|
| Concept/Terms |
Induction Chemotherapy- Induction Chemotherapy
- Chemotherapies, Induction
- Chemotherapy, Induction
- Induction Chemotherapies
|
Below are MeSH descriptors whose meaning is more general than "Induction Chemotherapy".
Below are MeSH descriptors whose meaning is more specific than "Induction Chemotherapy".
This graph shows the total number of publications written about "Induction Chemotherapy" by people in this website by year, and whether "Induction Chemotherapy" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 2 | 2 | 4 |
| 2012 | 5 | 3 | 8 |
| 2013 | 2 | 7 | 9 |
| 2014 | 2 | 3 | 5 |
| 2015 | 0 | 2 | 2 |
| 2016 | 4 | 6 | 10 |
| 2017 | 1 | 4 | 5 |
| 2018 | 4 | 5 | 9 |
| 2019 | 5 | 2 | 7 |
| 2020 | 2 | 0 | 2 |
| 2021 | 0 | 10 | 10 |
| 2022 | 0 | 6 | 6 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 6 | 6 |
| 2025 | 1 | 0 | 1 |
| 2026 | 0 | 3 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Induction Chemotherapy" by people in Profiles.
-
Toxicity from asparaginase during acute lymphoblastic leukemia induction: a report from the Children's Oncology Group. Blood Adv. 2026 07 28; 10(14):4923-4930.
-
Multiomic characterisation of the clinical efficacy of guselkumab induction therapy in ulcerative colitis. BMJ Open Gastroenterol. 2026 Mar 23; 13(1).
-
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial. Lancet Gastroenterol Hepatol. 2026 Apr; 11(4):284-298.
-
Treatment response after induction therapy in advanced thymic tumors: results from the Italian nationwide TYME database. Lung Cancer. 2026 Jan; 211:108871.
-
Guselkumab in patients with moderately to severely active ulcerative colitis (QUASAR): phase 3 double-blind, randomised, placebo-controlled induction and maintenance studies. Lancet. 2025 01 04; 405(10472):33-49.
-
Comparing Rituximab and Cyclophosphamide in Induction Therapy for Childhood-Onset Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis: An ARChiVe Registry Cohort Study. Arthritis Care Res (Hoboken). 2025 Apr; 77(4):504-512.
-
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial. Lancet Gastroenterol Hepatol. 2025 02; 10(2):138-153.
-
Blast Phase of Myeloproliferative Neoplasm Resembles Acute Myeloid Leukemia, Myelodysplasia-Related, in Clinical Presentation, Cytogenetic Pattern, and Genomic Profile, and Often Undergoes Reversion to Second Chronic Phase Status After Induction Chemotherapy. Arch Pathol Lab Med. 2024 12 01; 148(12):1310-1319.
-
Impact of induction regimens intensity and allogeneic stem cell transplantation on survival of patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A multi-institutional study. Am J Hematol. 2024 12; 99(12):2388-2391.
-
Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults. N Engl J Med. 2024 07 25; 391(4):320-333.